Extracted from this filing and checked against the source text.
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Sanara MedTech Inc. completed an acquisition involving The Hymed Group Corporation and Applied Nutritionals, LLC for $15.25 million (closed 2023-08-01).
- Action
- acquisition
- Counterparty
- The Hymed Group Corporation and Applied Nutritionals, LLC
- Consideration
- $15.25 million
- Closing
- 2023-08-01
Exact text from the filing
HYCOL Hydrolyzed Collagen (Powder and Gel) (“HYCOL”) products for human wound care use. The Purchased Assets were purchased for an initial aggregate purchase price of $15.25 million, consisting of (i) $9.75 million in cash (the “Cash Closing Consideration”), (ii) 73,809 shares of the Company’s common stock, par value $0.001 per share (the “Stock Closing
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Sanara MedTech Inc. entered into Asset Purchase Agreement with The Hymed Group Corporation, Applied Nutritionals, LLC, and Dr. George D. Petito valued at initial aggregate purchase price of $15.25 million (effective 2023-08-01).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- The Hymed Group Corporation, Applied Nutritionals, LLC, and Dr. George D. Petito
- Value
- initial aggregate purchase price of $15.25 million
- Effective
- 2023-08-01
Exact text from the filing
On August 1, 2023, Sanara MedTech Inc., a Texas corporation (the “Company”), entered into an Asset Purchase Agreement (the “Purchase Agreement”) by and among the Company, as guarantor, Sanara MedTech Applied Technologies, LLC, a Texas limited liability company and wholly owned subsidiary of the Company (the “Purchaser”), The Hymed Group Corporation, a Delaware corporation (“Hymed”), Applied Nutritionals, LLC, a Delaware limited liability company (“Applied” and, together with Hymed, the “Sellers”), and Dr. George D. Petito (the “Owner”)
View on SEC.gov